XmAb657

Phase 1

XXencor, Inc.

XmAb657 is one of 5 therapeutic programs targeting Idiopathic Inflammatory Myopathies. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Idiopathic Inflammatory MyopathiesRecruiting

Idiopathic Inflammatory MyopathiesPhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Idiopathic Inflammatory Myopathies

#DrugCompanyPhaseTrials

Fabhalta

Johnson & Johnson

Phase 2

1 2

Rapcabtagene Autoleucel

Novartis

Phase 2

1 3

Glucocorticoids

Novartis

Phase 2

1 4

Xmab13676

XXencor, Inc.

Phase 1

1 5

XmAb657

XXencor, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Idiopathic Inflammatory Myopathies

NCT07284797

Clinical

Trials by Indication[1]

Idiopathic Inflammatory Myopathies1 trial

A Phase 1, First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of XmAb657 in Healthy Participants and in Participants With Autoimmune Diseases

Recruiting·XXencor, Inc.·Phase 1·NCT07284797·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for XmAb657. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for XmAb657. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Xencor, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: XXencor, Inc.

XmAb657

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Idiopathic Inflammatory Myopathies1 trial

References

Drug Info

Quick Facts

Related News